Month: September 2020

I have great fun & satisfaction mentoring @IU_Health residents interested in #re…

[ad_1] I have great fun & satisfaction mentoring @IU_Health residents interested in #retina & #research. Congrats to these fantastic current & prior IU residents for this recent publication on a most-feared complication of #eye surgery:https://t.co/De83FjWyks [ad_2] Source by Thomas Ciulla, MD, MBA Return to main 

At this year’s Retina Society meeting, our team & colleagues had numerous presen…

[ad_1] At this year’s Retina Society meeting, our team & colleagues had numerous presentations on #retina clinical science as well as #suprachoroidal delivery of tyrosine kinase inhibitor, #genetherapy & corticosteroid. #eyes #ophthalmology #biotech #medicine #clinicalresearch #macula https://t.co/gyCPxPE17z [ad_2] Source by Thomas Ciulla, MD, MBA Return 

Diabetic macular edema treatment burden remains a significant barrier to meaning…

[ad_1]
Diabetic macular edema treatment burden remains a significant barrier to meaningfully positive real world outcomes. Longer acting and more effective treatments are needed…#diabetes #retina #eyes #clinicaltrials https://t.co/IhJVFCnOCZ
[ad_2]

Source by Thomas Ciulla, MD, MBA

Return to main website.

RT @1stOncology: #AuraBiosciences Announces Dosing of First Patient in Phase 2 S…

[ad_1] RT @1stOncology: #AuraBiosciences Announces Dosing of First Patient in Phase 2 Study Evaluating Suprachoroidal Administration of #AU011 in… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

RT @PharmacDaily: Clearside Biomedical’s Oncology Licensing Partner Doses First …

[ad_1] RT @PharmacDaily: Clearside Biomedical’s Oncology Licensing Partner Doses First Patient in its Phase 2 Study in Patients with Choroidal Mel… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

RT @OphthTimes: . @REGENXBIO announces dosing of first patient in AAVIATE phase…

[ad_1]
RT @OphthTimes: . @REGENXBIO announces dosing of first patient in AAVIATE phase II trial of RGX-314 for treatment of wet AMD using suprac…
[ad_2]

Source by Thomas Ciulla, MD, MBA

Return to main website.

Just co-authored this paper on integrin inhibition, a potentially important path…

[ad_1] Just co-authored this paper on integrin inhibition, a potentially important pathway for treatment of common causes of vision loss, #maculardegeneration and #diabeticretinopathy… #retina #ophthalmology #eyes #diabetes #biotech #drugdevelopment #medicine https://t.co/qI3dJQ8ya1 [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

RT @MDMagazine: .@REGENXBIO yesterday announced the clearance of the Investigati…

[ad_1] RT @MDMagazine: .@REGENXBIO yesterday announced the clearance of the Investigational New Drug application by the #FDA to evaluate suprachor… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

Recently interviewed for this article on #GeneTherapy: …

[ad_1]
Recently interviewed for this article on #GeneTherapy: https://t.co/UtFxhmVPQ8
[ad_2]

Source by Thomas Ciulla, MD, MBA

Return to main website.